[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Markets Direct: Market Research Reports

Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.

A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.

The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.

With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.

Under the supervision of skillful managers and experts, business analysts produce reports that include:

  • Product portfolio
  • Potentially strong market reviews
  • Competitive analytics
  • Prospect partners
  • Mergers and acquisitions project data
  • Latest trends across a particular industry area
  • Research and development strategies
  • The analysis of new customers
  • A set of remedial measures for projects

They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.

Publications found: 5,853
Sort by:

Interleukin 18 Receptor 1 (CD218 Antigen Like Family Member A or CDw218a or IL1 Receptor Related Protein or CD218a or IL18R1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 18 Receptor 1 (CD218 Antigen Like Family Member A or CDw218a or IL1 Receptor Related Protein or CD218a or IL18R1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, M...

May 2022 39 pages

Interleukin 2 Receptor Subunit Beta (High Affinity IL 2 Receptor Subunit Beta or Interleukin 15 Receptor Subunit Beta or p70-75 or CD122 or IL2RB) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 2 Receptor Subunit Beta (High Affinity IL 2 Receptor Subunit Beta or Interleukin 15 Receptor Subunit Beta or p70-75 or CD122 or IL2RB) Drugs in Development by Therapy Areas and Indications...

May 2022 58 pages

Interleukin 33 (Interleukin 1 Family Member 11 or IL1F11 or Nuclear Factor From High Endothelial Venules or NFHEV or IL33) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 33 (Interleukin 1 Family Member 11 or IL1F11 or Nuclear Factor From High Endothelial Venules or NFHEV or IL33) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mole...

May 2022 43 pages

Interleukin 6 (B Cell Stimulatory Factor 2 or BSF2 or CTL Differentiation Factor or CDF or Hybridoma Growth Factor or Interferon Beta 2 or IFNB2 or IL6) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 6 (B Cell Stimulatory Factor 2 or BSF2 or CTL Differentiation Factor or CDF or Hybridoma Growth Factor or Interferon Beta 2 or IFNB2 or IL6) Drugs in Development by Therapy Areas and Indic...

May 2022 53 pages

Interleukin 6 Receptor Subunit Beta (Membrane Glycoprotein 130 or Oncostatin M Receptor Subunit Alpha or Interleukin 6 Signal Transducer or gp130 or CD130 or IL6ST) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 6 Receptor Subunit Beta (Membrane Glycoprotein 130 or Oncostatin M Receptor Subunit Alpha or Interleukin 6 Signal Transducer or gp130 or CD130 or IL6ST) Drugs in Development by Therapy Are...

May 2022 37 pages

Isocitrate Dehydrogenase [NADP] Cytoplasmic (Oxalosuccinate Decarboxylase or Cytosolic NADP Isocitrate Dehydrogenase or IDP or NADP(+) Specific ICDH or IDH1 or EC 1.1.1.42) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Isocitrate Dehydrogenase [NADP] Cytoplasmic (Oxalosuccinate Decarboxylase or Cytosolic NADP Isocitrate Dehydrogenase or IDP or NADP(+) Specific ICDH or IDH1 or EC 1.1.1.42) Drugs in Development by The...

May 2022 42 pages

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mole...

May 2022 35 pages

Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154) Drugs in Development by Therapy...

May 2022 57 pages

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Drugs in Development by Therapy Areas and Indications, Stages, MoA, Ro...

May 2022 127 pages

Low Affinity Immunoglobulin Gamma Fc Region Receptor III A (Fc Gamma RIII Alpha or IgG Fc Receptor III-2 or CD16a or FCGR3A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Low Affinity Immunoglobulin Gamma Fc Region Receptor III A (Fc Gamma RIII Alpha or IgG Fc Receptor III-2 or CD16a or FCGR3A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mo...

May 2022 40 pages

Lysyl Oxidase Homolog 2 (Lysyl Oxidase Like Protein 2 or Lysyl Oxidase Related Protein 2 or Lysyl Oxidase Related Protein WS9-14 or LOXL2 or EC 1.4.3.13) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Lysyl Oxidase Homolog 2 (Lysyl Oxidase Like Protein 2 or Lysyl Oxidase Related Protein 2 or Lysyl Oxidase Related Protein WS9-14 or LOXL2 or EC 1.4.3.13) Drugs in Development by Therapy Areas and Indi...

May 2022 37 pages

Mannan Binding Lectin Serine Protease 2 (Mannose Binding Protein Associated Serine Protease 2 or MBL Associated Serine Protease 2 or MASP2 or EC 3.4.21.104) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Mannan Binding Lectin Serine Protease 2 (Mannose Binding Protein Associated Serine Protease 2 or MBL Associated Serine Protease 2 or MASP2 or EC 3.4.21.104) Drugs in Development by Therapy Areas and I...

May 2022 39 pages

Membrane Primary Amine Oxidase (Copper Amine Oxidase or Semicarbazide-Sensitive Amine Oxidase or Vascular Adhesion Protein 1 or HPAO or AOC3 or EC 1.4.3.21) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Membrane Primary Amine Oxidase (Copper Amine Oxidase or Semicarbazide-Sensitive Amine Oxidase or Vascular Adhesion Protein 1 or HPAO or AOC3 or EC 1.4.3.21) Drugs in Development by Therapy Areas and I...

May 2022 43 pages

Mineralocorticoid Receptor (Nuclear Receptor Subfamily 3 Group C Member 2 or Mineralocorticoid Receptor Delta or Aldosterone Receptor or MR or NR3C2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Mineralocorticoid Receptor (Nuclear Receptor Subfamily 3 Group C Member 2 or Mineralocorticoid Receptor Delta or Aldosterone Receptor or MR or NR3C2) Drugs in Development by Therapy Areas and Indicati...

May 2022 41 pages

Monoglyceride Lipase (Lysophospholipase Homolog or Lysophospholipase Like or HU K5 or Monoacylglycerol Lipase or MGLL or EC 3.1.1.23) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Monoglyceride Lipase (Lysophospholipase Homolog or Lysophospholipase Like or HU K5 or Monoacylglycerol Lipase or MGLL or EC 3.1.1.23) Drugs in Development by Therapy Areas and Indications, Stages, MoA...

May 2022 38 pages

Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT Lymphoma Associated Translocation or Paracaspase or MALT1 or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT Lymphoma Associated Translocation or Paracaspase or MALT1 or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications,...

May 2022 44 pages

Multidrug Resistance Protein 1 (ATP Binding Cassette Sub Family B Member 1 or P Glycoprotein 1 or CD243 or ABCB1 or EC 7.6.2.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Multidrug Resistance Protein 1 (ATP Binding Cassette Sub Family B Member 1 or P Glycoprotein 1 or CD243 or ABCB1 or EC 7.6.2.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 45 pages

Myotonin Protein Kinase (DM Kinase or DM1 Protein Kinase or Thymopoietin Homolog or Myotonin Protein Kinase A or Myotonic Dystrophy Associated Protein Kinase or DMPK or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Myotonin Protein Kinase (DM Kinase or DM1 Protein Kinase or Thymopoietin Homolog or Myotonin Protein Kinase A or Myotonic Dystrophy Associated Protein Kinase or DMPK or EC 2.7.11.1) Drugs in Developme...

May 2022 44 pages

NACHT LRR And PYD Domains Containing Protein 3 (Caterpiller Protein 1.1 or Cold Autoinflammatory Syndrome 1 Protein or Cryopyrin or Nucleotide Binding Oligomerization Domain Leucine Rich Repeat And Pyrin Domain Containing 3 or NLRP3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

NACHT LRR And PYD Domains Containing Protein 3 (Caterpiller Protein 1.1 or Cold Autoinflammatory Syndrome 1 Protein or Cryopyrin or Nucleotide Binding Oligomerization Domain Leucine Rich Repeat And Py...

May 2022 66 pages

NAD Dependent Protein Deacetylase Sirtuin 2 (Regulatory Protein SIR2 Homolog 2 or SIR2 Like Protein 2 or SIRT2 or EC 2.3.1.286) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

NAD Dependent Protein Deacetylase Sirtuin 2 (Regulatory Protein SIR2 Homolog 2 or SIR2 Like Protein 2 or SIRT2 or EC 2.3.1.286) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 39 pages

Natural Cytotoxicity Triggering Receptor 1 (Lymphocyte Antigen 94 Homolog or NK Cell Activating Receptor or Natural Killer Cell p46 Related Protein or CD335 or NCR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Natural Cytotoxicity Triggering Receptor 1 (Lymphocyte Antigen 94 Homolog or NK Cell Activating Receptor or Natural Killer Cell p46 Related Protein or CD335 or NCR1) Drugs in Development by Therapy Ar...

May 2022 40 pages

Nitric Oxide Synthase Inducible (Hepatocyte NOS or Inducible NO Synthase or Peptidyl Cysteine S Nitrosylase NOS2 or NOS Type II or NOS2 or EC 1.14.13.39) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Nitric Oxide Synthase Inducible (Hepatocyte NOS or Inducible NO Synthase or Peptidyl Cysteine S Nitrosylase NOS2 or NOS Type II or NOS2 or EC 1.14.13.39) Drugs in Development by Therapy Areas and Indi...

May 2022 41 pages

NKG2 D Type II Integral Membrane Protein (Killer Cell Lectin Like Receptor Subfamily K Member 1 or NK Cell Receptor D or NKG2 D Activating NK Receptor or CD314 or KLRK1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

NKG2 D Type II Integral Membrane Protein (Killer Cell Lectin Like Receptor Subfamily K Member 1 or NK Cell Receptor D or NKG2 D Activating NK Receptor or CD314 or KLRK1) Drugs in Development by Therap...

May 2022 39 pages

Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) Drugs in Devel...

May 2022 37 pages

P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y(cyc) or P2Y12 or P2RY12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y(cyc) or P2Y12 or P2RY12) Drugs in Development by Therapy Areas and Indications, Stages,...

May 2022 40 pages

Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial (Cyclophilin D or Cyclophilin F or Mitochondrial Cyclophilin or Rotamase F or PPIF or EC 5.2.1.8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial (Cyclophilin D or Cyclophilin F or Mitochondrial Cyclophilin or Rotamase F or PPIF or EC 5.2.1.8) Drugs in Development by Therapy Areas and Indicati...

May 2022 37 pages

Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN (Mutated In Multiple Advanced Cancers 1 or Phosphatase And Tensin Homolog or PTEN or EC 3.1.3.16 or EC 3.1.3.48 or EC 3.1.3.67) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN (Mutated In Multiple Advanced Cancers 1 or Phosphatase And Tensin Homolog or PTEN or EC 3.1.3.16 or...

May 2022 35 pages

Platelet Derived Growth Factor Receptor Alpha (Alpha Type Platelet Derived Growth Factor Receptor or CD140 Antigen Like Family Member A or Platelet Derived Growth Factor Receptor 2 or CD140a or PDGFRA or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Platelet Derived Growth Factor Receptor Alpha (Alpha Type Platelet Derived Growth Factor Receptor or CD140 Antigen Like Family Member A or Platelet Derived Growth Factor Receptor 2 or CD140a or PDGFRA...

May 2022 52 pages

Platelet Derived Growth Factor Receptor Beta (Beta Type Platelet Derived Growth Factor Receptor or CD140 Antigen Like Family Member B or Platelet Derived Growth Factor Receptor 1 or CD140b or PDGFRB or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Platelet Derived Growth Factor Receptor Beta (Beta Type Platelet Derived Growth Factor Receptor or CD140 Antigen Like Family Member B or Platelet Derived Growth Factor Receptor 1 or CD140b or PDGFRB o...

May 2022 62 pages

Platelet Glycoprotein 4 (Fatty Acid Translocase or Glycoprotein IIIb or Leukocyte Differentiation Antigen CD36 or PAS4 or Platelet Collagen Receptor or Platelet Glycoprotein IV or Thrombospondin Receptor or CD36) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Platelet Glycoprotein 4 (Fatty Acid Translocase or Glycoprotein IIIb or Leukocyte Differentiation Antigen CD36 or PAS4 or Platelet Collagen Receptor or Platelet Glycoprotein IV or Thrombospondin Recep...

May 2022 37 pages

Poly [ADP Ribose] Polymerase 3 (ADP Ribosyltransferase Diphtheria Toxin Like 3 or NAD(+) ADP Ribosyltransferase 3 or Poly[ADP Ribose] Synthase 3 or PARP3 or EC 2.4.2.30) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Poly [ADP Ribose] Polymerase 3 (ADP Ribosyltransferase Diphtheria Toxin Like 3 or NAD(+) ADP Ribosyltransferase 3 or Poly[ADP Ribose] Synthase 3 or PARP3 or EC 2.4.2.30) Drugs in Development by Therap...

May 2022 36 pages

Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) Drugs in Development by Therapy Areas and I...

May 2022 40 pages

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) Drugs in Development by...

May 2022 49 pages

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Drugs in Development by Therapy Areas and Indi...

May 2022 46 pages

Prostaglandin E Synthase (Microsomal Glutathione S Transferase 1 Like 1 or Microsomal Prostaglandin E Synthase 1 or p53 Induced Gene 12 Protein or PTGES or EC 5.3.99.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Prostaglandin E Synthase (Microsomal Glutathione S Transferase 1 Like 1 or Microsomal Prostaglandin E Synthase 1 or p53 Induced Gene 12 Protein or PTGES or EC 5.3.99.3) Drugs in Development by Therapy...

May 2022 43 pages

Prostatic Acid Phosphatase (5 Nucleotidase or Ecto 5 Nucleotidase or Thiamine Monophosphatase or ACPP or EC 3.1.3.2 or EC 3.1.3.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Prostatic Acid Phosphatase (5 Nucleotidase or Ecto 5 Nucleotidase or Thiamine Monophosphatase or ACPP or EC 3.1.3.2 or EC 3.1.3.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, R...

May 2022 35 pages

Proteasome Subunit Beta Type 8 (Low Molecular Mass Protein 7 or Macropain Subunit C13 or Multicatalytic Endopeptidase Complex Subunit C13 or Proteasome Component C13 or Proteasome Subunit Beta 5i or PSMB8 or EC 3.4.25.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Proteasome Subunit Beta Type 8 (Low Molecular Mass Protein 7 or Macropain Subunit C13 or Multicatalytic Endopeptidase Complex Subunit C13 or Proteasome Component C13 or Proteasome Subunit Beta 5i or P...

May 2022 35 pages

Protein Arginine N Methyltransferase 5 (Shk1 Kinase Binding Protein 1 Homolog or Jak Binding Protein 1 or Histone Arginine N Methyltransferase PRMT5 or 72 kDa ICln Binding Protein or PRMT5 or EC 2.1.1.320) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Protein Arginine N Methyltransferase 5 (Shk1 Kinase Binding Protein 1 Homolog or Jak Binding Protein 1 or Histone Arginine N Methyltransferase PRMT5 or 72 kDa ICln Binding Protein or PRMT5 or EC 2.1.1...

May 2022 52 pages

Protein Mdm4 (Double Minute 4 Protein or Mdm2 Like p53 Binding Protein or Protein Mdmx or p53 Binding Protein Mdm4 or MDM4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Protein Mdm4 (Double Minute 4 Protein or Mdm2 Like p53 Binding Protein or Protein Mdmx or p53 Binding Protein Mdm4 or MDM4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mol...

May 2022 35 pages

Protein O GlcNAcase (Beta Hexosaminidase or Beta N Acetylhexosaminidase or N Acetyl Beta Glucosaminidase or Meningioma Expressed Antigen 5 or Nuclear Cytoplasmic O GlcNAcase And Acetyltransferase or MGEA5 or EC 3.2.1.169) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Protein O GlcNAcase (Beta Hexosaminidase or Beta N Acetylhexosaminidase or N Acetyl Beta Glucosaminidase or Meningioma Expressed Antigen 5 or Nuclear Cytoplasmic O GlcNAcase And Acetyltransferase or M...

May 2022 37 pages

Proto Oncogene Tyrosine Protein Kinase Receptor Ret (Cadherin Family Member 12 or Proto Oncogene c Ret or RET or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Proto Oncogene Tyrosine Protein Kinase Receptor Ret (Cadherin Family Member 12 or Proto Oncogene c Ret or RET or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, M...

May 2022 80 pages

Pyruvate Kinase PKM (Cytosolic Thyroid Hormone Binding Protein or Pyruvate Kinase Muscle Isozyme or Opa Interacting Protein 3 or Pyruvate Kinase 2-3 or Tumor M2 PK or PKM2 or Thyroid Hormone Binding Protein 1 or p58 or PKM or EC 2.7.1.40) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Pyruvate Kinase PKM (Cytosolic Thyroid Hormone Binding Protein or Pyruvate Kinase Muscle Isozyme or Opa Interacting Protein 3 or Pyruvate Kinase 2-3 or Tumor M2 PK or PKM2 or Thyroid Hormone Binding P...

May 2022 36 pages

Receptor Activity Modifying Protein 2 (Calcitonin Receptor Like Receptor Activity Modifying Protein 2 or CRLR Activity Modifying Protein 2 or RAMP2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Receptor Activity Modifying Protein 2 (Calcitonin Receptor Like Receptor Activity Modifying Protein 2 or CRLR Activity Modifying Protein 2 or RAMP2) Drugs in Development by Therapy Areas and Indicatio...

May 2022 38 pages

Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1) Drugs in Developm...

May 2022 113 pages

Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2...

May 2022 173 pages

Retinal Specific ATP Binding Cassette Transporter (ATP Binding Cassette Sub Family A Member 4 or RIM ABC Transporter or Stargardt Disease Protein or ABCA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Retinal Specific ATP Binding Cassette Transporter (ATP Binding Cassette Sub Family A Member 4 or RIM ABC Transporter or Stargardt Disease Protein or ABCA4) Drugs in Development by Therapy Areas and In...

May 2022 41 pages

Retinoic Acid Receptor RXR Alpha (Nuclear Receptor Subfamily 2 Group B Member 1 or Retinoid X Receptor Alpha or NR2B1 or RXRA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Retinoic Acid Receptor RXR Alpha (Nuclear Receptor Subfamily 2 Group B Member 1 or Retinoid X Receptor Alpha or NR2B1 or RXRA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 39 pages

Retinoid Isomerohydrolase (All Trans Retinyl Palmitate Hydrolase or Retinal Pigment Epithelium Specific 65 kDa Protein or Retinol Isomerase or RPE65 or EC 3.1.1.64) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Retinoid Isomerohydrolase (All Trans Retinyl Palmitate Hydrolase or Retinal Pigment Epithelium Specific 65 kDa Protein or Retinol Isomerase or RPE65 or EC 3.1.1.64) Drugs in Development by Therapy Are...

May 2022 37 pages

Sigma Non Opioid Intracellular Receptor 1 (Aging Associated Gene 8 Protein or SR31747 Binding Protein or Sigma 1 Type Opioid Receptor or SIGMAR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sigma Non Opioid Intracellular Receptor 1 (Aging Associated Gene 8 Protein or SR31747 Binding Protein or Sigma 1 Type Opioid Receptor or SIGMAR1) Drugs in Development by Therapy Areas and Indications,...

May 2022 59 pages

Filters

Search

Categories

2,264
2,910
126
9
6
1
1
1
4
522
3
6

Publishers

5,853

Regions

5,853

Price

Date

Pages

Offers